Highlights Revenues of $2,429 million, up 34% compared to the same period last year, a record for a first quarter in the Company s history; Normalized EBITDA.
11.05.2023 - Agreement reached with FDA on confirmatory Phase 3 clinical trial design for sabizabulin treatment of hospitalized COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS), including two planned interim efficacy analyses .
/PRNewswire/ Driven Brands Holdings Inc. (NASDAQ: DRVN) ("Driven Brands" or the "Company") today reported financial results for the first quarter ended.
FORT WAYNE, Ind., May 01, 2023 Vera Bradley, Inc. today provided an update on its environmental, social, and governance efforts as demonstrated by the three pillars of Caring for People,. | May 1, 2023